Table 1

Baseline demographics and disease characteristics of the patients according to concomitant cDMARD or MTX use at baseline subdivided by treatment group

Concomitant treatmentcDMARDMTXNone (cDMARD-naïve or past use at baseline)
PBO, n=69IXEQ4W, n=68IXEQ2W, n=63PBO, n=59IXEQ4W, n=57IXEQ2W, n=53PBO, n=37IXEQ4W, n=39IXEQ2W, n=40
Age (years), mean (SD)51.0 (12.5)49.1 (10.0)49.3 (12.8)51.3 (12.8)49.9 (10.3)50.1 (12.7)49.9 (12.1)49.1 (10.4)50.5 (12.4)
Male, n (%)32 (46.4)29 (42.6)27 (42.9)25 (42.4)24 (42.1)23 (43.4)16 (43.2)16 (41.0)21 (52.5)
Weight (kg), mean (SD)84.8 (19.7)83.5 (19.5)81.0 (16.7)84.87 (20.1)84.58 (20.0)81.88 (15.8)81.8 (19.6)88.9 (28.0)82.6 (18.8)
Time since PsA diagnosis (years), mean (SD)6.1 (7.4)5.6 (5.8)7.4 (7.4)6.1 (7.6)5.1 (5.3)7.8 (7.8)6.8 (5.8)7.3 (7.3)7.0 (9.1)
Tender joint count (68 joints), mean (SD)19.5 (12.8)20.6 (13.3)21.4 (15.1)20.6 (13.4)20.5 (13.8)21.1 (15.6)18.6 (13.4)20.3 (14.4)21.8 (12.4)
Swollen joint count (66 joints), mean (SD)10.9 (7.7)10.8 (7.4)11.8 (7.6)11.3 (8.1)10.8 (7.9)11.4 (6.0)10.1 (6.4)12.6 (9.4)12.5 (6.7)
HAQ-DI total score, mean (SD)1.19 (0.60)1.25 (0.54)1.23 (0.55)1.21 (0.60)1.21 (0.53)1.25 (0.57)1.09 (0.62)1.22 (0.56)1.09 (0.59)
van der Heijde mTSS, mean (SD)18.9 (32.2)21.2 (36.9)17.3 (32.7)17 (28.6)21 (38.4)19.2 (35.2)15.3 (21.6)15.7 (23.9)11.9 (21.4)
  • The study was not designed to test equivalence or non-inferiority of treatment with ixekizumab alone versus treatment with ixekizumab combined with cDMARDs.

  • cDMARD, conventional disease-modifying antirheumatic drugs; HAQ-DI, Health Assessment Questionnaire-Disability Index; IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab once every 4 weeks; mTSS, modified total Sharp score; MTX, methotrexate; n, number of patients; PBO, placebo; PsA, psoriatic arthritis.